Navigation Links
OncoGenex Pharmaceuticals to Webcast Presentations at September Investor Conferences

BOTHELL, WA and VANCOUVER, Sept. 3 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the company will webcast presentations at the following investor conferences:

    -   Rodman & Renshaw 11th Annual Healthcare Conference on Thursday,
        September 10, 2009 at 12:30 p.m. Eastern Time in the Fahnestock Salon
        at the New York Palace Hotel in New York City.

    -   Thomas Weisel Partners Healthcare Conference on Friday, September 11,
        2009 at 10:20 a.m. Eastern Time in the Stuart Room at the Four
        Seasons Hotel in Boston.

    -   BioCentury NewsMakers in the Biotech Industry Conference on
        Wednesday, September 16, 2009 at 2:30 p.m. Eastern Time in room
        304/305 at the Millennium Broadway Hotel & Conference Center in New
        York City.

Access to a live webcast of each of the presentations will be available on the Events Presentation section of the Investor Relations page on the company Web site at A replay of each webcast will be available for 30 days following the event.

About OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate that has completed five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical develo

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
(Date:10/7/2015)... ... October 07, 2015 , ... ... webinar titled Smart Nanostructured Coatings to provide a comprehensive overview of the innovations ... free webinar at . This webinar will be given by Professor ...
(Date:10/7/2015)... Menlo Park, CA and Yokahama, Japan (PRWEB) , ... ... ... Sugiyama Lab at RIKEN have entered into a collaborative agreement to develop a ... interactions (DDIs). , Optivia and the Sugiyama Lab will combine their respective ...
(Date:10/6/2015)... ... October 06, 2015 , ... Researchers ... microscope technology that could help surgeons work with a greater degree of accuracy. ... blood flow and cancerous tissue over real images of blood vessels and other ...
(Date:10/6/2015)... , Oct. 6, 2015  The nonprofit ... that natural ingredients manufacturer Teawolf has adopted the ... Adopt-an-Herb Program . HerbMedPro ™ database ... clinical research on guayusa, a caffeine-containing member of ... comprehensive database available on ABC,s website that provides ...
Breaking Biology Technology:
... Networks Corp. has been recognized by Microsoft ... services. , ,The Madison-based IT solutions provider this month ... Midwest to achieve Microsoft's Enterprise Project Management (EPM) specialization. ... expertise in serving businesses that require the tools and ...
... Wis. Higher revenue from its clinical molecular diagnostic products ... a loss for the quarter ending March 31, 2006. , ,Third ... of $4.4 million, or ($0.11) a diluted share, for the first ... net loss of $4.4 million, or ($0.11) a diluted share, for ...
... Wis. Fiserv, which provides software and services ... revenues in 2006 were up 13 percent to $1.1 ... from the $140 million the company made in the ... , ,Fiserve's activities in the first quarter included repurchasing ...
Cached Biology Technology:
(Date:9/28/2015)... , September 28, 2015 ... Component (Hardware & Software), Product (Scanner & Others), Application ... & Defense, & Others) & Geography Global - Forecast ... expected to reach USD 3627.90 Million by 2020, at ... Browse 65 market data T ables ...
(Date:9/24/2015)... , Sept. 24, 2015  EyeLock LLC, a ... showcasing its award winning and latest technology in Booth ... Anaheim, California . EyeLock,s iris authentication ... with unmatched biometric accuracy, making it the most proven ... platform uses video technology to deliver a fast and ...
(Date:9/10/2015)... LONDON , Sept. 10, 2015 ... This New Study Reveals Selling Opportunities and Revenue ... What,s the future of biologics, especially new drug ... You will stay ahead with exclusive market data ... can explore trends, developments, results, opportunities and sales ...
Breaking Biology News(10 mins):
... is often compared to a book. However, it is not so ... rather like a cookbook. The cell reads only those recipes which ... genes; ,reading, in the book of the cell means creating RNA ... The cell uses highly complex, sophisticated regulatory mechanisms to ...
... have created mice that can "smell" light, providing a potent ... basis of olfaction. The work, described this week in ... future study of smell and of complex perception systems that ... "It makes intuitive sense to use odors to study ...
... thousand federal, state and local leaders and physical security ... Regional Airport next May 17-19 to observe demonstrations of ... to personnel, equipment and facilities - in combat zones ... and abroad. Military and civilian representatives of ...
Cached Biology News:
... for all types of yeast two-hybrid studies, including complex ... Choice of two bait vectors for maximum ... Triple reporter strain NMY51 ... Complete set of controls: pLexA-p53, pLexA-lamin ...
... Quickly, effectively seals labware. Waterproof, ... protects anhydrous materials. Can be folded ... without rupturing. Stretched lengthwise at 21C ... Yet when tension is removed, film ...
Human Serum FDA Licensed US Donor Centers Sterile / Non-sterile: Sterile Filtered to 0.2 micron Information: Extensive Viral Testing ...
Normal human serum collected off the clot from healthy normal humans. Each donor unit is negative for anti-HIV 1&2, HIV-Ag, HCV, and HBsAg by FDA required tests...
Biology Products: